Page last updated: 2024-12-05

2'-deoxyadenosine triphosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2'-deoxyadenosine triphosphate: RN given refers to unlabeled parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

deoxyadenosine diphosphate: RN given refers to parent cpd. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID15993
CHEMBL ID335538
CHEBI ID16284
SCHEMBL ID78250
MeSH IDM0087218
PubMed CID188966
CHEBI ID16174
SCHEMBL ID77641
MeSH IDM0087218

Synonyms (89)

Synonym
einecs 217-662-3
brn 0071964
[(2r,3s,5r)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methyl (hydroxy-phosphonooxyphosphoryl) hydrogen phosphate
gtpl1760
2'-deoxy-5'-atp
adenosine 5'-(tetrahydrogen triphosphate), 2'-deoxy- (9ci)
2'-deoxy-atp
2'-deoxyadenosine 5'-(tetrahydrogen triphosphate)
5'-datp
adenosine, 2'-deoxy-, 5'-triphosphate (6ci,7ci)
2'-datp
adenosine, 2'-deoxy-, 5'-(tetrahydrogen triphosphate) (8ci)
9h-purin-6-amine, 9-[2-deoxy-5-o-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-beta-d-erythro-pentofuranosyl]-
adenosine, 5'-(tetrahydrogen triphosphate), 2'-deoxy-
adenosine, 2'-deoxy-, 5'-(tetrahydrogen triphosphate)
CHEBI:16284 ,
C00131
DATP ,
2'-deoxyadenosine-5'-triphosphate
2'-deoxyadenosine 5'-triphosphate
deoxy-atp
2'-deoxyadenosine triphosphate
1927-31-7
deoxyadenosine triphosphate
deoxyadenosine 5'-triphosphate
[[(2r,3s,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] phosphono hydrogen phosphate
DB03222
1H7A
CHEMBL335538 ,
atp,2'-deoxy
bdbm50118233
2''-deoxyadenosine 5''-(tetrahydrogen triphosphate)
[[(2r,3s,5r)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
4-26-00-03593 (beilstein handbook reference)
unii-k8kcc8sh6n
k8kcc8sh6n ,
67460-17-7
d-erythro-pentitol, 1-c-(7-amino-1h-pyrazolo(4,3-d)pyrimidin-3-yl)-1,4-anhydro-2-deoxy-, 5-(tetrahydrogen triphosphate), (r)-
2'-deoxyformycin-5'-triphosphate
EPITOPE ID:149167
SCHEMBL78250
AKOS022179909
(((2r,3s,5r)-5-(6-amino-9h-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl)triphosphoric acid
2'-deoxyadenosine-5'-triphosphate trisodium salt
adenosine 5'-(tetrahydrogen triphosphate), 2'-deoxy-
deoxy-atp, 2'-deoxyadenosine triphosphate, deoxyadenosine 5'-triphosphate
deoxy[ 3h]adenosine 5'-triphosphate
AC-8231
AS-69027
({[({[(2r,3s,5r)-5-(6-amino-9h-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)phosphonic acid
HY-136648
CS-0132807
111907-01-8
DTXSID10895848
Q201090
(((2r,3s,5r)-5-(6-amino-9h-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl)triphosphoricacid
A852110
deoxyadenosine diphosphate
2'-deoxyadenosine 5'-(trihydrogen diphosphate)
CHEBI:16174
adenosine, 2'-deoxy-, 5'-pyrophosphate
adenosine, 2'-deoxy-, 5'-pyrophosphate (6ci,7ci)
2'-deoxyadenosine diphosphate
deoxyadenosine 5'-diphosphate
adenosine, 2'-deoxy-, 5'-(trihydrogen pyrophosphate)
adenosine 5'-(trihydrogen diphosphate), 2'-deoxy- (9ci)
adenosine, 2'-deoxy-, 5'-(trihydrogen pyrophosphate) (8ci)
9h-purin-6-amine, 9-[2-deoxy-5-o-[hydroxy(phosphonooxy)phosphinyl]-beta-d-erythro-pentofuranosyl]-
2'-deoxyadenosine 5'-pyrophosphate
2'-deoxyadenosine-5'- diphosphate
C00206
2793-06-8
2'-deoxyadenosine 5'-diphosphate
2'-deoxyadenosine-5'-diphosphate
DADP ,
BMSE000253
72003-83-9
unii-apq916i0qd
apq916i0qd ,
2'-deoxyadenosine-5'-diphosphate disodium salt
SCHEMBL77641
2'-deoxy-adp
deoxy-adp
adenosine 5'-(trihydrogen diphosphate), 2'-deoxy-
Q27098417
DTXSID90950621
PD165867
[5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methyl phosphono hydrogenphosphate
((2r,3s,5r)-5-(6-amino-9h-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl trihydrogen diphosphate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The mechanism by which 2'-deoxyguanosine is toxic for lymphoid cells is relevant both to the severe cellular immune defect of inherited purine nucleoside phosphorylase (PNP) deficiency and to attempts to exploit PNP inhibitors therapeutically."( Deoxyadenosine triphosphate as a mediator of deoxyguanosine toxicity in cultured T lymphoblasts.
Fox, RM; Mann, GJ, 1986
)
0.27

Pharmacokinetics

ExcerptReferenceRelevance
" Based on these clinical, pharmacokinetic, and pharmacodynamic data, Triapine warrants further study in patients with hematologic malignancies."( Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
Alvarado, Y; Brown, RA; Cahill, A; Cortes, JE; DiPersio, JF; Faderl, S; Fracasso, PM; Gandhi, V; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Lambert, P; Plunkett, W; Samson, T; Sznol, M; Thomas, DA; Verstovsek, S; Wright, LP, 2003
)
0.32

Dosage Studied

ExcerptRelevanceReference
" A dose-response analysis demonstrated that the concentration of deoxycoformycin at which there was 50% inhibition of growth was greater than 1 X 10(-3) M in lymphoblastoid cells."( In vitro metabolism of deoxycoformycin in human T lymphoblastoid cells. Phosphorylation of deoxycoformycin and incorporation into cellular DNA.
Coleman, MS; Siaw, MF, 1984
)
0.27
"Ara-C at very low dosage has been reported to decrease the host toxicity of ara-AMP or ara-A in combination with 2'-deoxycoformycin, a potent adenosine deaminase inhibitor, while increasing the toxicity to intracerebral L1210 leukemia."( Biochemical and biophysical approaches to improving the anticancer effectiveness of Ara-adenine.
Eyring, H; Miles, DL; Miles, DW, 1982
)
0.26
" Dose-response experiments analyzing the dependence of cell death on drug concentration indicated a marked resistance of BAF3bcl-2 to FDUR treatment."( Bcl-2 oncogene protects a bone marrow-derived pre-B-cell line from 5'-fluor,2'-deoxyuridine-induced apoptosis.
Collins, MK; López-Rivas, A; Marvel, J; Oliver, FJ, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
2'-deoxyadenosine 5'-phosphate
purine 2'-deoxyribonucleoside 5'-triphosphate
2'-deoxyadenosine 5'-phosphate
purine 2'-deoxyribonucleoside 5'-diphosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (34)

PathwayProteinsCompounds
Purine Metabolism3766
Adenosine Deaminase Deficiency3766
Adenylosuccinate Lyase Deficiency3766
Gout or Kelley-Seegmiller Syndrome3766
Lesch-Nyhan Syndrome (LNS)3766
Molybdenum Cofactor Deficiency3766
Xanthine Dehydrogenase Deficiency (Xanthinuria)3766
Purine Nucleoside Phosphorylase Deficiency3766
AICA-Ribosiduria3766
Azathioprine Action Pathway4782
Mercaptopurine Action Pathway4780
Thioguanine Action Pathway4781
Xanthinuria Type I3766
Xanthinuria Type II3766
Adenine Phosphoribosyltransferase Deficiency (APRT)3766
Mitochondrial DNA Depletion Syndrome-33766
Myoadenylate Deaminase Deficiency3766
Mitochondrial DNA Depletion Syndrome3566
Purine nucleotides and Nucleosides metabolism ( Purine nucleotides and Nucleosides metabolism )10577
ATP + dADP = ADP + dATP ( Purine nucleotides and Nucleosides metabolism )74
The impact of Nsp14 on metabolism (COVID-19 Disease Map)084
purine nucleotide metabolism (phosphotransfer and nucleotide modification)023
purine nucleotides de novo biosynthesis I039
superpathway of histidine, purine, and pyrimidine biosynthesis064
Photosynthetic carbon reduction014
Crystal toxin triggered necrosis pathway03
AMPK signaling06
AMP-activated protein kinase signaling06
Thyroxine (thyroid hormone) production010
Endothelin pathways013
Nanoparticle triggered regulated necrosis26
Biochemical pathways: part I0466
NAD+ metabolism014
ATP + dAMP = ADP + dADP ( Purine nucleotides and Nucleosides metabolism )44

Protein Targets (7)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, ANAEROBIC RIBONUCLEOTIDE-TRIPHOSPHATE REDUCTASE LARGE CHAINTequatrovirus T4Kd19.000013.000016.000019.0000AID977611
Chain A, ANAEROBIC RIBONUCLEOTIDE-TRIPHOSPHATE REDUCTASE LARGE CHAINTequatrovirus T4Kd19.000013.000016.000019.0000AID977611
P2Y purinoceptor 1Meleagris gallopavo (turkey)EC50 (µMol)19.00000.00251.70498.0000AID150470
Reverse transcriptase/RNaseH Human immunodeficiency virus 1Kd4.92860.00062.40599.8000AID395722; AID395723; AID572771; AID618865; AID618875; AID670143; AID670146
P2Y purinoceptor 11Homo sapiens (human)EC50 (µMol)9.00000.06313.77049.0000AID150489
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
S-adenosylmethionine synthase isoform type-2Rattus norvegicus (Norway rat)Km4,000.00005.00005.00005.0000AID107904
Reverse transcriptase/RNaseH Human immunodeficiency virus 1Km0.41000.07001.91446.9000AID167233; AID167235; AID198921; AID711539
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
defense responseP2Y purinoceptor 11Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 11Homo sapiens (human)
activation of adenylate cyclase activityP2Y purinoceptor 11Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 11Homo sapiens (human)
calcium-mediated signalingP2Y purinoceptor 11Homo sapiens (human)
neuronal signal transductionP2Y purinoceptor 11Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 11Homo sapiens (human)
cellular response to ATPP2Y purinoceptor 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
neurotransmitter receptor activityP2Y purinoceptor 11Homo sapiens (human)
signaling receptor activityP2Y purinoceptor 11Homo sapiens (human)
G protein-coupled ATP receptor activityP2Y purinoceptor 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneP2Y purinoceptor 11Homo sapiens (human)
plasma membraneP2Y purinoceptor 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (46)

Assay IDTitleYearJournalArticle
AID22610Kinetic parameter Vmax was determined2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
2-Amino-7-deazaadenine forms stable base pairs with cytosine and thymine.
AID670148Inhibition of wild type HIV1 reverse transcriptase assessed as compound incorporation efficiency in presence of 50 nM primer template and 10 mM MgCl2 by pre-steady state kinetics study2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Pre-steady state kinetic analysis of cyclobutyl derivatives of 2'-deoxyadenosine 5'-triphosphate as inhibitors of HIV-1 reverse transcriptase.
AID711522Activity of HIV1 reverse transcriptase assessed per unit of protein2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Synopsis of some recent tactical application of bioisosteres in drug design.
AID395726Inhibition of HIV1 wild type reverse transcriptase p66/p51 DNA polymerase activity assessed as formation of terminated DNA products2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro suppression of K65R reverse transcriptase-mediated tenofovir- and adefovir-5'-diphosphate resistance conferred by the boranophosphonate derivatives.
AID1124518Effect on human mitochondrial thymidine kinase using [14C]thymidine at 5 mM after 10 mins by liquid scintillation spectrometer analysis relative to control in presence of Mg2+1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Design of species- or isozyme-specific enzyme inhibitors. 1. Effect of thymidine substituents on affinity for the thymidine site of hamster cytoplasmic thymidine kinase.
AID618865Binding affinity to HIV1 reverse transcriptase assessed as L-3'-azido-NTP incorporation in nascent DNA2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides.
AID107761Relative maximum velocity against liver (MAT-I) in rat methionine adenosyltransferase was reported1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Isozyme-specific enzyme inhibitors. 10. Adenosine 5'-triphosphate derivatives as substrates or inhibitors of methionine adenosyltransferases of rat normal and hepatoma tissues.
AID670145Inhibition of HIV1 reverse transcriptase K65R mutant assessed as compound incorporation efficiency in presence of 50 nM primer template and 10 mM MgCl2 by pre-steady state kinetics study2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Pre-steady state kinetic analysis of cyclobutyl derivatives of 2'-deoxyadenosine 5'-triphosphate as inhibitors of HIV-1 reverse transcriptase.
AID670146Binding affinity to HIV1 reverse transcriptase K65R mutant by pre-steady state kinetics study2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Pre-steady state kinetic analysis of cyclobutyl derivatives of 2'-deoxyadenosine 5'-triphosphate as inhibitors of HIV-1 reverse transcriptase.
AID395724Binding affinity to wild type reverse transcriptase assessed as ratio of catalytic rate constant to Kd for incorporation of drug to DNA by gel electrophoresis2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro suppression of K65R reverse transcriptase-mediated tenofovir- and adefovir-5'-diphosphate resistance conferred by the boranophosphonate derivatives.
AID150470Evaluated for agonist activity against phospholipase C coupled P2Y purinoceptor 1 (P2Y1) of turkey erythrocytes2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID395722Binding affinity to HIV1 wild type reverse transcriptase p66/p51 expressed in Escherichia coli assessed as incorporation of drug to DNA by gel electrophoresis2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro suppression of K65R reverse transcriptase-mediated tenofovir- and adefovir-5'-diphosphate resistance conferred by the boranophosphonate derivatives.
AID107766Inhibitory constant against rat liver Methionine adenosyltransferase I1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Isozyme-specific enzyme inhibitors. 10. Adenosine 5'-triphosphate derivatives as substrates or inhibitors of methionine adenosyltransferases of rat normal and hepatoma tissues.
AID572772Ratio of Kpol to Kd for HIV1 reverse transcriptase2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572770Activity at HIV1 reverse transcriptase measured after 30 mins2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID198921Substrate Activity against HIV-1 Reverse transcriptase wild-type (RT wt)2003Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
Inhibition of human immunodeficiency virus reverse transcriptase by synadenol triphosphate and its E-isomer.
AID572771Binding affinity to HIV1 reverse transcriptase2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID18096Kinetic parameter Km was determined2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
2-Amino-7-deazaadenine forms stable base pairs with cytosine and thymine.
AID294601Ratio of Vmax to Km for 9 Nm DNA polymerase2007Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8
Synthesis and recognition of novel isonucleoside triphosphates by DNA polymerases.
AID670143Binding affinity to wild type HIV1 reverse transcriptase by pre-steady state kinetics study2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Pre-steady state kinetic analysis of cyclobutyl derivatives of 2'-deoxyadenosine 5'-triphosphate as inhibitors of HIV-1 reverse transcriptase.
AID711538Ratio of Vmax to Km for HIV1 reverse transcriptase2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Synopsis of some recent tactical application of bioisosteres in drug design.
AID294600Activity of 9 Nm DNA polymerase enzyme2007Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8
Synthesis and recognition of novel isonucleoside triphosphates by DNA polymerases.
AID107763Inhibitory potency against rat Methionine adenosyltransferase I1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Isozyme-specific enzyme inhibitors. 10. Adenosine 5'-triphosphate derivatives as substrates or inhibitors of methionine adenosyltransferases of rat normal and hepatoma tissues.
AID167235Substrate Activity against HIV-1 reverse transcriptase (RT M184V)2003Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
Inhibition of human immunodeficiency virus reverse transcriptase by synadenol triphosphate and its E-isomer.
AID395723Binding affinity to HIV1 recombinant reverse transcriptase p66/p51 K65R mutant expressed in Escherichia coli assessed as incorporation of drug to DNA by gel electrophoresis2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro suppression of K65R reverse transcriptase-mediated tenofovir- and adefovir-5'-diphosphate resistance conferred by the boranophosphonate derivatives.
AID107907Relative maximum velocity against rat Methionine adenosyltransferase II1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Isozyme-specific enzyme inhibitors. 10. Adenosine 5'-triphosphate derivatives as substrates or inhibitors of methionine adenosyltransferases of rat normal and hepatoma tissues.
AID670147Binding affinity to HIV1 reverse transcriptase K65R mutant assessed as compound incorporation in presence of 50 nM primer template and 10 mM MgCl2 by pre-steady state kinetics study2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Pre-steady state kinetic analysis of cyclobutyl derivatives of 2'-deoxyadenosine 5'-triphosphate as inhibitors of HIV-1 reverse transcriptase.
AID395725Binding affinity to HIV1 recombinant reverse transcriptase p66/p51 K65R mutant expressed in Escherichia coli assessed as ratio of catalytic rate constant to Kd for incorporation of drug to DNA by gel electrophoresis2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro suppression of K65R reverse transcriptase-mediated tenofovir- and adefovir-5'-diphosphate resistance conferred by the boranophosphonate derivatives.
AID618875Binding affinity to HIV1 reverse transcriptase M184V mutant assessed as L-3'-azido-NTP incorporation in nascent DNA2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides.
AID107751Relative maximum velocity against rat methionine adenosyltransferase was reported; Not determined1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Isozyme-specific enzyme inhibitors. 10. Adenosine 5'-triphosphate derivatives as substrates or inhibitors of methionine adenosyltransferases of rat normal and hepatoma tissues.
AID107772Inhibitory potency against rat Methionine adenosyltransferase II1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Isozyme-specific enzyme inhibitors. 10. Adenosine 5'-triphosphate derivatives as substrates or inhibitors of methionine adenosyltransferases of rat normal and hepatoma tissues.
AID150489Agonist activity against phospholipase C coupled human P2Y purinoceptor 11 (P2Y11)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID1124517Effect on human cytoplasmic thymidine kinase using [14C]thymidine at 5 mM after 10 mins by liquid scintillation spectrometer analysis relative to control in presence of Mg2+1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Design of species- or isozyme-specific enzyme inhibitors. 1. Effect of thymidine substituents on affinity for the thymidine site of hamster cytoplasmic thymidine kinase.
AID395727Inhibition of HIV1 wild type reverse transcriptase p66/p51 R72A mutant DNA polymerase activity assessed as formation of terminated DNA products2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro suppression of K65R reverse transcriptase-mediated tenofovir- and adefovir-5'-diphosphate resistance conferred by the boranophosphonate derivatives.
AID107904Inhibitory constant against rat kidney Methionine adenosyltransferase II1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Isozyme-specific enzyme inhibitors. 10. Adenosine 5'-triphosphate derivatives as substrates or inhibitors of methionine adenosyltransferases of rat normal and hepatoma tissues.
AID618876Ratio Kpol to Kd for wild type HIV 1 reverse transcriptase2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides.
AID53665Km value with DNA polymerase alpha2002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Enhancement of nucleoside cytotoxicity through nucleotide prodrugs.
AID671283Binding affinity to wild type HIV1 reverse transcriptase assessed as compound incorporation in presence of 50 nM primer template and 10 mM MgCl2 by pre-steady state kinetics study2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Pre-steady state kinetic analysis of cyclobutyl derivatives of 2'-deoxyadenosine 5'-triphosphate as inhibitors of HIV-1 reverse transcriptase.
AID229453Efficiency expressed as ratio of Vmax to that of Km was determined2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
2-Amino-7-deazaadenine forms stable base pairs with cytosine and thymine.
AID618877Ratio Kpol to Kd for wild type HIV 1 reverse transcriptase M184V mutant2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides.
AID167233Substrate Activity against HIV-1 reverse transcriptase (RT M184I)2003Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
Inhibition of human immunodeficiency virus reverse transcriptase by synadenol triphosphate and its E-isomer.
AID711539Activity of HIV1 reverse transcriptase2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Synopsis of some recent tactical application of bioisosteres in drug design.
AID1124515Effect on thymidine kinase in BHK21 (C13) cells using [14C]thymidine at 5 mM after 10 mins by liquid scintillation spectrometer analysis relative to control in presence of Mg2+1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Design of species- or isozyme-specific enzyme inhibitors. 1. Effect of thymidine substituents on affinity for the thymidine site of hamster cytoplasmic thymidine kinase.
AID1346335Human P2Y11 receptor (P2Y receptors)1999British journal of pharmacology, Nov, Volume: 128, Issue:6
Pharmacological characterization of the human P2Y11 receptor.
AID1811Experimentally measured binding affinity data derived from PDB2001Structure (London, England : 1993), Aug, Volume: 9, Issue:8
Structural basis for allosteric substrate specificity regulation in anaerobic ribonucleotide reductases.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2001Structure (London, England : 1993), Aug, Volume: 9, Issue:8
Structural basis for allosteric substrate specificity regulation in anaerobic ribonucleotide reductases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (520)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990135 (25.96)18.7374
1990's133 (25.58)18.2507
2000's149 (28.65)29.6817
2010's89 (17.12)24.3611
2020's14 (2.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.33 (24.57)
Research Supply Index6.27 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index22.26 (26.88)
Search Engine Supply Index1.60 (0.95)

This Compound (24.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (0.77%)5.53%
Trials0 (0.00%)5.53%
Reviews12 (2.30%)6.00%
Reviews0 (0.00%)6.00%
Case Studies11 (2.11%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other495 (94.83%)84.16%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]